Piramal Pharma Sustainability Report 2025-26
Analysis based on 16 articles · First reported Jul 20, 2026 · Last updated Aug 26, 2026
The release of the sustainability report is likely to have a modest positive impact on Piramal Group's reputation among ESG-focused investors, potentially supporting its stock price. The US$90 million investment in advanced therapeutics capabilities signals growth and may enhance long-term revenue prospects, though the immediate market reaction is expected to be limited.
Piramal Group Limited released its Sustainability Report 2025-26 on August 26, 2026, highlighting significant progress in environmental, social, and governance (ESG) priorities. The company achieved a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared to the FY2022 baseline, increased renewable energy usage to 41% of total energy consumption, recycled and reused 2.63 lakh kilolitres of freshwater, and diverted 65% of total waste for recycling. In quality and operational excellence, Piramal Group completed 38 regulatory inspections, including three USFDA inspections with zero Official Action Indicated (OAI) observations, and 209 customer audits. The company also announced a US$90 million investment to expand advanced therapeutics capabilities at its Lexington and Riverview facilities. Governance highlights include zero data breach incidents, zero corruption cases, 100% ESG training completion, and women representing 30% of the Board and 20.1% of the global workforce. During FY2025-26, Piramal Group invested ₹8.98 crore in CSR initiatives, positively impacting nearly 1.8 million people across 112 Aspirational Districts. Chairperson Nandini Piramal emphasized sustainability as a catalyst for innovation and long-term growth. The report follows GRI standards and aligns with SASB and UNGC frameworks.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard